Sugi Predict

Sugi Predict / Compounds / SCHEMBL30101593

SCHEMBL30101593

SCHEMBL30101593

CCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.87
▸ ERBB2 P04626 13/20 0.87
▸ ERBB4 Q15303 2/20 0.73
▸ CIT O14578 1/20 0.73
▸ GAK O14976 1/20 0.73
▸ EPHB6 O15197 1/20 0.73
▸ RIPK2 O43353 1/20 0.73
▸ STK10 O94804 1/20 0.73
▸ ABL1 P00519 1/20 0.73
▸ LCK P06239 1/20 0.73
▸ LYN P07948 1/20 0.73
▸ RET P07949 1/20 0.73
▸ CHRM2 P08172 1/20 0.73
▸ MET P08581 1/20 0.73
▸ HCK P08631 1/20 0.73
▸ SRC P12931 1/20 0.73
▸ PHKG2 P15735 1/20 0.73
▸ ADRA2B P18089 1/20 0.73
▸ ERBB3 P21860 1/20 0.73
▸ AXL P30530 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639014 1.00 EGFR (0.87) EGFRERBB2ERBB4CITGAK
SCHEMBL17538538 0.93 EGFR (1.00) EGFRERBB2ERBB4CITGAK
SCHEMBL867638 0.93 EGFR (0.85) EGFRERBB2ERBB4CITGAK
SCHEMBL867639 0.93 EGFR (0.85) EGFRERBB2ERBB4CITGAK
SCHEMBL20325402 0.93 EGFR (0.83) EGFRERBB2ERBB4CITGAK
SCHEMBL17538473 0.92 EGFR (1.00) EGFRERBB2ERBB4CITGAK
SCHEMBL25859410 0.92 EGFR (0.78) EGFRERBB2ERBB4JAK3
SCHEMBL19639023 0.92 EGFR (0.74) EGFRERBB2ERBB4CITGAK
SCHEMBL23154276 0.91 EGFR (0.77) EGFRERBB2ERBB4JAK3
SCHEMBL25859411 0.91 EGFR (0.77) EGFRERBB2ERBB4JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683635-A1 USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR Boundless Bio, Inc. (US) 2026-01-28 — — EP claimed
WO-2025049814-A2 RIBONUCLEOTIDE REDUCTASE (RNR) COMPOSITIONS AND METHODS OF USE BOUNDLESS BIO, INC. (US) 2025-03-06 — — WO claimed
WO-2024196923-A1 USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR BOUNDLESS BIO, INC. (US) 2024-09-26 — — WO claimed
US-20240108633-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) 2024-04-04 — — US claimed
CN-121586709-A Checkpoint kinase 1 (CHK 1) inhibitor crystal forms and uses thereof 无界生物公司 2026-02-27 — — CN disclosed
EP-4688770-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF Boundless Bio, Inc. (US) 2026-02-11 — — EP disclosed
EP-4683635-A1 USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR Boundless Bio, Inc. (US) 2026-01-28 — — EP disclosed
US-12527790-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2026-01-20 — — US disclosed
EP-4626433-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF Boundless Bio, Inc. (US) 2025-10-08 — — EP disclosed
EP-4532486-A1 PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF Boundless Bio, Inc. (US) 2025-04-09 — — EP disclosed
WO-2025049814-A2 RIBONUCLEOTIDE REDUCTASE (RNR) COMPOSITIONS AND METHODS OF USE BOUNDLESS BIO, INC. (US) 2025-03-06 — — WO disclosed
CN-119546588-A Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof 无界生物公司 2025-02-28 — — CN disclosed
CN-117715905-A Checkpoint kinase 1 (CHK 1) inhibitors and uses thereof 无界生物公司 2024-03-15 — — CN disclosed
WO-2023230477-A1 PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. (US) 2023-11-30 — — WO disclosed
CN-117042771-A Methods of treating cancer using a combination of SERD dosing regimens 伊莱利利公司 2023-11-10 — — CN disclosed
CN-116981451-A Pharmaceutical composition for treating breast cancer and method of use thereof 田纳西大学研究基金会 2023-10-31 — — CN disclosed
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-10-05 — — US disclosed
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2023-07-25 — — US disclosed
US-20230026313-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-01-26 — — US disclosed
WO-2022251502-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. (US) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 EGFR 2007/4885ERBB2 1198/4885ERBB4 1422/4885
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof CHEK1, CHEK2, RAD1 EGFR 2007/4885ERBB2 1198/4885ERBB4 1422/4885
US-20230026313-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 EGFR 2007/4885ERBB2 1198/4885ERBB4 1422/4885
US-12527790-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof CHEK1, RAD1, CHEK2 EGFR 371/4885ERBB2 279/4885ERBB4 802/4885
US-20240108633-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT JAK2, JAK1, JAK3 EGFR 439/4885ERBB2 191/4885ERBB4 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.